Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 5/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seratrodast SCHEMBL98403 | 0.90 | TBXAS1 (0.52) | TBXA2RTBXAS1 | |
| SCHEMBL9308117 | 0.90 | TBXAS1 (0.52) | TBXA2RTBXAS1 | |
| Seratrodast SCHEMBL98402 | 0.90 | TBXAS1 (0.52) | TBXA2RTBXAS1 | |
| SCHEMBL2458688 | 0.90 | TBXA2R (0.59) | TBXA2RTBXAS1SLC6A3PTGER1PTGFR | |
| SCHEMBL9309433 | 0.90 | TBXA2R (0.44) | TBXA2RTBXAS1SLC6A3 | |
| SCHEMBL9308585 | 0.89 | TBXAS1 (0.50) | TBXA2RTBXAS1SLC6A3 | |
| SCHEMBL2453660 | 0.87 | PDE4B (0.44) | TBXA2RTBXAS1PTGFRKMT2AFFAR1 | |
| SCHEMBL9309249 | 0.87 | PTGER2 (0.37) | TBXA2RTBXAS1SLC6A3PTGER2 | |
| SCHEMBL7828928 | 0.87 | HDAC1 (0.49) | — | |
| SCHEMBL2460183 | 0.86 | PDE4B (0.45) | TBXA2RTBXAS1PTGFRKMT2AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5534548-A | Method of treating preeclampsia | TAP PHARMACEUTICALS, INC. (US) | 1996-07-09 | — | — | US | claimed |
| WO-1995029671-A1 | BENZOQUINON ALKANOIC ACIDS FOR TREATING PREECLAMPSIA | TAP HOLDINGS INC. (US) | 1995-11-09 | — | — | WO | claimed |
| US-5180742-A | Lipoxygenase Inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-19 | — | — | US | claimed |
| EP-0171251-B2 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-12-23 | — | — | EP | claimed |
| EP-0171251-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-06-27 | — | — | EP | claimed |
| EP-0171251-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-02-12 | — | — | EP | claimed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-5534548-A | Method of treating preeclampsia | TAP PHARMACEUTICALS, INC. (US) | 1996-07-09 | — | — | US | disclosed |
| WO-1995029671-A1 | BENZOQUINON ALKANOIC ACIDS FOR TREATING PREECLAMPSIA | TAP HOLDINGS INC. (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | TBXA2R 3935/4885TBXAS1 3817/4885SLC6A3 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.